FOLH1 and metastatic neoplasm: Newer molecular imaging agents, including prostate-specific membrane antigen (PSMA)-PET/CT and fluciclovine-PET/CT, have substantially improved the detection of metastatic disease that otherwise would have gone undetected on conventional imaging [4].